

Erlacher, Miriam

Dr. med. univ., PhD; *09.10.1978; female

Physician scientist / Pediatric Hematologist and Oncologist
Division of Pediatric Hematology and Oncology
Department of Pediatrics and Adolescent Medicine
Medical Center University Freiburg
Mathildenstr. 1 – D-79106 Freiburg
Tel: +49 (761) 207 43010
Email: miriam.erlacher@uniklinik-freiburg.de

Current position

Pediatric Hematologist and Oncologist (50%)
Principal investigator (50%) of the research group “Apoptosis signaling in hematopoiesis and leukemogenesis”
Principal investigator of the German Cancer Consortium (DKTK)

University training and degrees

27.09.2007 PhD, Innsbruck Medical University, Austria
2003-2007 PhD student, Innsbruck Medical University, Program: Molecular Oncology
24.06.2003 Dr. med. univ. (MD), Leopold-Franzens University Innsbruck, Austria
1997-2003 MD student, Leopold-Franzens University Innsbruck, Austria

Advanced academic qualifications

20.10.2015 Board certification in pediatric hematology and oncology, Germany
06.03.2013 Board certification in pediatric and adolescent medicine, Germany
2010 Board certification for leading clinical trials as a principal investigator (Prüfarzt)
21.02.2007 License to practice medicine (Approbation)
2003-2007 PhD thesis, Innsbruck Medical University, Division of Developmental Immunology (Prof. A. Villunger)
2000-2002 MD thesis, Innsbruck Medical University, Institute of Experimental Pathophysiology and Immunology (Prof. A. Wick)

Postgraduate Positions

since 2015 Pediatric hematologist and oncologist, Division of Pediatric Hematology and Oncology, University Medical Center Freiburg
2013-2015 Fellow in pediatric hematology and oncology, Division of Pediatric Hematology and Oncology, University Medical Center Freiburg
since 2009 Principal investigator (own funding and personnel)
2007-2013 Resident, Department of Pediatrics and Adolescent Medicine, University Medical Center Freiburg
2006 Internship (Tirocinio), Hospital of Sterzing, Italy

Fellowship and Awards

2015 ERC starting grant for the project “ApoptoMDS”
2013-2014 FRIAS Junior Fellowship, University of Freiburg
2013 Research prize of the Deutsche Arbeitsgemeinschaft für Knochenmark- und Blutstammzelltransplantation
2010 Fellowship for Translational Research Training in Hematology (TRTH), European Hematology Association (EHA) and the American Society for Hematology (ASH)
2009-2013 Margarete von Wrangell-Fellowship, Ministerium für Wissenschaft, Forschung und Kunst in Baden-Württemberg and the European Social Fund
2006 Thesis award, Austrian Society of Allergology and Immunology (for PhD thesis)
2006 Sanofi-Aventis-Award, Innsbruck Medical University

Publications (selection)

1. Buonocore F*, Kühnen P*, Suntharalingham JP, Del Valle I, Digweed M, Stachelscheid H, Khajavi N, Didi M, Brady AF, Blankenstein O, Procter AM, Dimitri P, Wales JKH, Ghirri P, Knöbl D, Strahm B, **Erlacher M**, Chen W, Anderson G, Morrogh D, Moulding DA, McKee SA, Niemeyer CM, Grütters A*, Achermann J*. Deleterious growth restricting effects of human SAMD9 mutations are rescued by dynamic genomic changes. *J Clin Invest* 2017 *in press*.
2. Krombholz CF, Aumann K, Kollek M, Bertele D, Fluhr S, Kunze M, Niemeyer CM, Flotho C, **Erlacher M**. Long-term serial xenotransplantation of juvenile myelomonocytic leukemia recapitulates human disease in Rag2(-/-) gamma c(-/-) mice. *Haematologica*. Mai 2016;101(5):597–606.
3. Labi V, Woess C, Tuzlak S, **Erlacher M**, Bouillet P, Strasser A, Tzankov A, Villunger A. Deregulated cell death and lymphocyte homeostasis cause premature lethality in mice lacking the BH3-only proteins Bim and Bmf. *Blood*. 24. April 2014;123(17):2652–62.
4. Carnevalli LS, Scognamiglio R, Cabezas-Wallscheid N, Rahmig S, Laurenti E, Masuda K, Joeckel L, Kuck A, Sujer S, Polykratis A, **Erlacher M**, Pasparakis M, Essers MAG, Trumpp A. Improved HSC reconstitution and protection from inflammatory stress and chemotherapy in mice lacking granzyme B. *Journal of Experimental Medicine*. 5. Mai 2014;211(5):769–79.
5. Labi V, Bertele D, Woess C, Tischner D, Bock FJ, Schwemmers S, Pahl HL, Geley S, Kunze M, Niemeyer CM, Villunger A, **Erlacher M**. Haematopoietic stem cell survival and transplantation efficacy is limited by the BH3-only proteins Bim and Bmf. *EMBO Molecular Medicine*. Januar 2013;5(1):122–36.
6. Niemeyer CM, Kang MW, Shin DH, Furlan I, **Erlacher M**, Bunin NJ, Bunda S, Finklestein JZ, Sakamoto KM, Gorr TA, Mehta P, Schmid I, Kropshofer G, Corbacioglu S, Lang PJ, Klein C, Schlegel P-G, Heinzmann A, Schneider M, Stary J, van den Heuvel-Eibrink MM, Hasle H, Locatelli F, Sakai D, Archambeault S, Chen L, Russell RC, Sybingco SS, Ohh M, Braun BS, Flotho C, Loh ML. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. *Nature Genetics*. September 2010;42(9):794-U93.
7. Labi V, **Erlacher M**, Krumschnabel G, Manzl C, Tzankov A, Pinon J, Egle A, Villunger A. Apoptosis of leukocytes triggered by acute DNA damage promotes lymphoma formation. *Genes & Development*. 1. August 2010;24(15):1602–7.
8. Labi V, **Erlacher M**, Kiessling S, Manzl C, Frenzel A, O'Reilly L, Strasser A, Villunger A. Loss of the BH3-only protein Bmf impairs B cell homeostasis and accelerates γ irradiation-induced thymic lymphoma development. *Journal of Experimental Medicine*. 17. März 2008;205(3):641–55.
9. **Erlacher M**, Labi V, Manzl C, Boeck G, Tzankov A, Haecker G, Michalak E, Strasser A, Villunger A. Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction. *Journal of Experimental Medicine*. 25. Dezember 2006;203(13):2939–51.
10. **Erlacher M**, Michalak E, Kelly P, Labi V, Niederegger H, Coultas L, Adams J, Strasser A, Villunger A. BH3-only proteins Puma and Bim are rate-limiting for gamma-radiation- and glucocorticoid-induced apoptosis of lymphoid cells in vivo. *Blood*. 15. Dezember 2005;106(13):4131–8.